Why ISF's Genetic Study Is Expanding to More Residents

A study only gets more useful as more people choose to be part of it.

The resident study led by Integrated Senior AI (ISAI), in partnership with Integrated Senior Foundation and Insight Living, is entering its next phase as more residents join across communities. It builds on an initial phase already underway, and the growth reflects a shared aim: advancing research that measurably improves health outcomes and quality of life for older adults.

The study centers on the APOE gene, which plays an important role in brain health. According to the National Institute on Aging, the ε4 form of APOE is the strongest known genetic risk factor for late-onset Alzheimer's, with risk rising for those who carry two copies, though many carriers never develop the disease [1]. Using a simple cheek swab, the study collects genetic insight that helps care teams understand the diversity of brain health profiles among residents, information that can inform personalized wellness and cognitive programs built to protect mental sharpness, independence, and long-term well-being.

The intent is to move from reactive care to proactive prevention. By identifying patterns that may signal early cognitive change, care teams can intervene to keep residents active, engaged, and connected for longer. Families have been notably supportive, recognizing that while the immediate benefit to any one participant varies, the broader value of the research extends well beyond today's residents.

That is the logic of building depth rather than breadth. Each consented participant adds to a continuous, longitudinal picture of how people age, the kind of dense, per-resident measurement researchers call deep phenotyping. Participation is voluntary, and resident data is handled under ISF's privacy, consent, and governance standards.

APOE is also an active research frontier. NIA-funded teams are still working out why ε4 raises risk and what appears to protect some carriers from it, which is precisely the kind of question a real-world, consented cohort like ISF's is positioned to help answer [2].

As the cohort grows, so does its value, both to the residents in it now and to the science of healthy aging that will serve those who come after them.